NCT00553631View on ClinicalTrials.gov

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 29, 2008

Primary Completion Date

May 5, 2009

Study Completion Date

May 5, 2009

Conditions
Gaucher Disease, Type 1
Interventions
BIOLOGICAL

velaglucerase alfa

IV infusion, 60 U/kg every other week for 9 months

BIOLOGICAL

imiglucerase

IV infusion, 60 U/kg every other week for 9 months

Trial Locations (11)

27710

Duke Children's Hospital & Health Center, Durham

B1882AQY

Your Health S.A., Buenos Aires

673 016

Malabar Institute of Medical Sciences Ltd., Calicut

110 029

All India Institute of Medical Sciences, New Delhi

Unknown

KEM Hospital Research Centre, Pune

Shaare Zedek Medical Center, Jerusalem

Sociedad Espanola de Socorros Mutuos, Asunción

National Research Center for Haematology, Moscow

Hospital Universitario Miguel Servet, Zaragoza

La Rabta Hospital, Tunis

The Royal Free Hospital, London

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT00553631 - Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease | Biotech Hunter | Biotech Hunter